Allosteric inhibitors of the kinase mammalian target of rapamycin (mTOR) have demonstrated significant clinical activity in patients with advanced renal cell carcinoma (RCC). Unfortunately, substantial clinical responses to these rapalogues are seen only in a subset of patients with advanced RCC. Preclinical studies have identified multiple theoretical shortcomings of the rapalogues, and numerous novel agents directed against the phosphatidylinositol 3-kinase/Akt/mTOR pathway, which address many of these shortcomings, are in active clinical development. In this review, we discuss the preclinical and clinical experience with the rapalogues in RCC, potential mechanisms of resistance to the rapalogues, and the progress in the clinical development of novel agents directed against the phosphatidylinositol 3-kinase/Akt/ mTOR pathway.
T he therapeutic relevance of the signaling pathway regulated by mammalian target of rapamycin (mTOR) in renal cell carcinoma (RCC) has been established by the clinical efficacy of allosteric inhibitors of this kinase. Two such rapalogues, temsirolimus and everolimus, are now approved by the US Food and Drug Administration (FDA) for the treatment of patients with advanced RCC. 1, 2 Unfortunately, significant clinical responses to these agents are experienced by only a subset of patients. Not surprisingly, developing predictive models to identify this subset of patients before treatment has been a priority for RCC researchers. At the same time, much effort has been committed to developing more effective therapies targeting this signaling pathway including therapies aimed at targets upstream of mTOR such as phosphatidylinositol 3-kinase (PI3K) and Akt (protein kinase B). In this article, we review the scientific rationale for mTOR as a therapeutic target, clinical data with current rapalogues, the scientific rationale for novel therapeutic approaches, novel agents in development, preclinical studies with these novel agents, and the clinical experience thus far.
RATIONALE FOR mTOR AS A THERAPEUTIC TARGET
Mammalian target of rapamycin exists in 2 functionally distinct complexes, which are distinguished by their relative sensitivity to rapamycin. TORC1, a complex including raptor (regulatory-associated protein of TOR), is sensitive to rapamcyin, whereas TORC2, a complex including rictor (rapamycininsensitive companion of TOR), is relatively resistant to rapamcyin. TORC2 appears to function as part of the PI3K pathway and activates Akt (through phosphorylation of the Ser473 residue) and serum-and glucocorticoid-regulated kinase 1 (SGK1). TORC1 appears to regulate the majority of functions that have been canonically associated with mTOR and acts through its downstream effectors, the p70 S6 kinase (S6K) and the eukaryotic initiation factor 4E-binding proteins (4E-BP1 and 4E-BP2), to regulate protein synthesis and cap-dependent translation. TORC1 directly phosphorylates S6K to activate ribosomal biosynthesis. The phosphorylation of the 4E-BPs by TORC1 causes them to disassociate from their binding partner, eIF4E, and thereby liberate it to interact with the 5 ¶ UTR of capped messenger RNA (mRNA) and initiate cap-dependent translation. Although the p70RSK and the 4E-BPs have traditionally been thought of as the primary TORC1 substrates, additional substrates are emerging. Recently, the adapter protein growth factor receptorYbound protein 10 (Grb10) has been described as a major substrate of TORC1 and shown to act as a negative regulator of PI3K through direct interaction with insulin response substrate 1. 3 The therapeutic efficacy of the rapalogues in RCC was discovered largely serendipitously through clinical investigation, prompting many subsequent investigations exploring the possible mechanisms for the observed clinical effect. Many initial hypotheses surrounded the effect of the rapalogues on the expression of hypoxia-inducible factors (HIF) 1 and 2. The inappropriate accumulation of HIF-1> and HIF-2> as a result of biallelic alterations in the von HippelYLindau (VHL) gene has been shown to be a major step in tumorigenesis of the majority of clear cell RCC. 4, 5 Following studies suggesting that mTOR activation may increase HIF-1> gene expression, both at the levels of mRNA translation and protein stabilization, many investigators proposed that the attenuation of HIF-1> expression might underlie the efficacy of the rapalogues in RCC. 6, 7 Many recent findings, however, cast some doubt upon this possibility. First, although the overlap between the roles of HIF-1> and HIF-2> is poorly understood, it is generally accepted that HIF-2> is the more relevant HIF with respect to the development and progression of RCC. 8, 9 In fact, recent studies suggest that HIF-1> may function as a tumor suppressor in clear cell RCC. 10 Another recent study segregating VHL-deficient sporadic RCC into 2 subtypes, those expressing both HIF-1> and HIF-2> and those expressing HIF-2> alone, found no specimens expressing HIF-1> alone. 11 Second, it has been suggested that the expression of HIF-1> is dependent on the activity of both TORC1 and TORC2, whereas the expression of HIF-2> is dependent on TORC2 activity alone. 12 As TORC2 activity is felt to be relatively resistant to inhibition by the rapalogues, the hypothesis that the mechanism of action of the rapalogues in RCC may be mediated by attenuation of HIF activity must be considered far from proven.
An alternative possibility remains that the rapalogues may attenuate the translation of critical mRNA in RCC. Although the translation of all capped mRNAs depends on the availability and activity of eIF4E, the translation of certain transcripts, in particular those with complicated 5 ¶ UTRYcontaining stem loop structures, is especially eIF4E-dependent and therefore highly susceptible to the suppressive effects of TORC1 inhibitors. 13 This group of difficult-to-translate mRNAs includes the transcripts of several genes relevant to cell cycle progression and transformation such as cyclin D, VEGF (vascular endothelial growth factor), survivin, and c-myc. The suppression of the expression of these gene products may therefore be a primary mode of efficacy of the rapalogues in RCC.
CLINICAL DATA WITH RAPALOGUES
Whereas the mechanism of action of the rapalogues in RCC remains unclear, the clinical efficacy of these agents is well established, and both temsirolimus and everolimus have demonstrated clinical efficacy in large randomized phase III trials in patients with advanced RCC. Temsirolimus is an intravenously administered analog of rapamycin. After showing promising activity in a phase II trial randomizing patients with metastatic RCC to 3 different doses, 14 temsirolimus was assessed in a randomized 3-arm phase III trial comparing temsirolimus alone versus interferon > (IFN->) alone versus the combination. 1 As the phase II study suggested potentially unique efficacy in patients with poor prognostic features in a retrospective analysis, the phase III study enrolled only patients with metastatic RCC and 3 or more of the 6 risk factors (5 Memorial Sloan-Kettering Cancer Center risk factors (Karnofsky Performance Status G80; time from diagnosis to randomization G12 months; serum lactate dehydrogenase 91.5 upper limit of normal; hemoglobin less than lower limit of normal; corrected serum calcium 910 mg/dL; plus 91 metastatic site). Overall, 626 previously untreated patients were enrolled and randomized in a 1:1:1 fashion to receive IFN-> alone (3 million units 3 times weekly), temsirolimus (25 mg i.v. weekly) alone, or the combination (temsirolimus 15 mg weekly and 6 million units IFN-> 3 times weekly). The overall survival of patients treated with temsirolimus alone was statistically longer than those treated with IFN-> alone (7.3 vs 10.9 months; hazard ratio, 0.73; P = 0.0069). There was no statistical difference between patients treated with IFN-> alone and the combination of IFN-> and temsirolimus. Based on these findings, temsirolimus was approved by the FDA for therapy in advanced RCC on May 30, 2007, and is now considered a standard therapeutic option in the first-line setting for patients with poor prognosis features.
Everolimus is an orally administered rapalogue and was assessed in a randomized, double-blind, placebo-controlled phase III trial in patients with advanced RCC who had failed prior treatment with either sorafenib, sunitinib, or both within the preceding 6 months (RECORD-1 [REnal Cell cancer treatment with Oral RAD001 given Daily 1]). 2 Overall, 416 patients were enrolled and randomized in a 2:1 fashion to receive either everolimus (n = 277) or placebo (n = 139) each together with best supportive care. The primary endpoint was progressionfree survival (PFS), randomization was unblinded at time of progression, and patients on placebo were allowed to cross over to open-label everolimus. At the final central radiology assessment, the median PFS for patients treated with everolimus was 4.88 months as compared with 1.87 months in the placebo group (hazard ratio, 0.33 [95% confidence interval, 0.25Y0.43; P G 0.0001). 15 Based on these findings, everolimus was approved by the FDA in March 2009 for the treatment of patients with advanced RCC who failed either sorafenib, sunitinib, or both and is now considered a standard second-line therapeutic option following the failure of VEGF-targeted tyrosine kinase inhibitor.
MECHANISM OF RESISTANCE TO RAPALOGUES IN RCC
Despite the clear activity of the rapalogues in RCC, it must be noted that substantial anti-tumor responses are limited to a subset of patients treated with these agents. Therefore, much effort has been directed at identifying possible mechanisms of resistance to these agents. Perhaps the most well-described shortcoming of the rapalogues is their potential to induce the feedback activation of PI3K and Akt. Many investigators have shown that treatment with rapamycin can result in the upstream activation of both PI3K, although a feedback loop involving the insulinlike growth factor 1 receptor and Akt through derepression of TORC2 results in TORC2-mediated phosphorylation of Akt on Ser473. 16, 17 PI3K/Akt signaling activates an array of kinases, transcription factors, and other proteins besides mTOR, which promote cell growth and survival. 18, 19 These prosurvival effects include the phosphorylation and nuclear export of FOXO3a, which reduces the expression of Fas ligand, Bim, and other proapoptotic proteins. Phosphatidylinositol 3-kinase activation also results in the downstream activation of nuclear factor JB and the inactivation of proapoptotic proteins such as BAD and procaspase 9. Activation of any of these prosurvival signals may have effects, which counteract the anti-tumor activity of the rapalogues. Finally, the feedback activation of PI3K may also directly undermine the efficacy of rapalogues by promoting the phosphorylation of eIF4E by Mnk1, thereby enhancing its affinity for the mRNA cap structure and activating cap-dependent translation. 20 Many investigators have also implicated the relatively limited efficacy of the rapalogues against the entire array of mTOR-regulated functions. As noted earlier, the kinase activity of mTOR in TORC2 is felt to be relatively resistant to the effects of rapalogues. This may be particularly relevant in the largely HIF-2>Ydriven clear cell RCC, given the aforementioned dependence of HIF-2> expression on TORC2 activity. Furthermore, it is becoming increasingly clear that the phosphorylation of the 4E-BPs is less responsive to rapalogues than that of S6K and S6 ribosomal protein, and the suppression of 4E-BP1 phosphorylation by rapamycin can be reversed within a few hours of drug exposure. 21, 22 Therefore, the attenuation of cap-dependent translation of critical mRNA, proposed to be a major mechanism of the anti-tumor effect of rapalogues, may only be a transient event.
DRUGS IN DEVELOPMENT
Not surprisingly, many of the novel agents targeting the PI3K/Akt/mTOR axis directly address some of the proposed shortcomings of the rapalogues. Some the earliest agents to enter clinical assessment have been pan-isoform inhibitors of PI3K. These agents are direct inhibitors of the kinase activity of the p110> catalytic subunit of class IA PI3Ks that act as ATP mimetics, binding competitively and reversibly to the p110 ATP-binding pocket. As PI3K/Akt is a major activator of mTOR kinase activity, inhibition of PI3K would be expected to attenuate mTOR activity in a majority of cancer types in a manner that may be free of the aforementioned feedback loops. Several such agents in active clinical development are noted in Table 1 .
The activity of TORC1, however, responds to many inputs other than PI3K/Akt signaling and can be activated independently of PI3K/Akt signaling through multiple mechanisms including through the liver kinase B1Vmonophosphate-activated protein kinase pathway and the mitogen-activating protein kinase pathway. 23, 24 TORC1 can also be activated in response to amino acid availability in a manner that is independent of tuberous sclerosis complexes 1 and 2 at the lysosomal membrane through the RAG-GTPases. 25 Therefore, there may be some cancers in which the inhibition of PI3K does not reliably result in the downstream inhibition of mTOR activity. For that reason, there may be additional benefit to inhibiting both PI3K and mTOR simultaneously. Structural similarities between the ATPbinding domain of p110> subunit of PI3K and the catalytic domain of mTOR have led to the development of a class of agents that are pan-isoform inhibitors of both PI3K and mTOR. Unlike the available rapalogues, these agents are active site inhibitors of mTOR and have the theoretical advantage of inhibiting the kinase activity of mTOR regardless of whether it is in complex with raptor (TORC1) or rictor (TORC2). Table 1 . A few of these agents such as GDC-0980 and BEZ235 have entered phase II clinical trials in RCC specifically.
Several dual PI3K/mTOR inhibitors in active clinical development are listed in
Additional agents in active clinical development include active site inhibitors of mTOR alone, isoform-specific PI3K inhibitors, and inhibitors of Akt. The active site inhibitors of mTOR inhibit the kinase function of both TORC1 and TORC2 while sparing PI3K. The primary theoretical advantage of the isoform-specific PI3K inhibitors is that they may have more focused toxicities compared with the pan-isoform inhibitors, allowing these agents to be tolerated at doses, which can result in more complete and reliable inhibition of kinase activity. Thus far, however, no particular PI3K isoform has been implicated as more relevant in RCC, and the utility of the isoform-specific agents in this disease remains to be seen. Like the PI3K inhibitors, Akt inhibitors are slowly advancing through clinical assessment. Among the inhibitors in clinical development are both allosteric inhibitors such as MK2206 and ATP-competitive catalytic inhibitors such as GSK690693 and GDC-0941. These agents thus far are all pan-isoform inhibitors of Akt.
PRECLINICAL DATA
Preclinical studies with PI3K inhibitors in RCC have supported the hypothesis that these agents may have activity in RCC. Inhibition of PI3K/Akt signaling by PI3K inhibitors LY294002 and wortmannin resulted in significant reduction in cell proliferation and induction of tumor cell apoptosis by both TUNEL (terminal deoxytransferase uridine triphosphate nick end-labeling) and propidium iodide staining in RCC cell lines (786-0). 26 Treatment of nude mice bearing RCC xenografts derived from the 786-O cells with LY294002 resulted in up to 50% reduction in tumor size. We have also observed that treatment of nude beige mice bearing RCC xenografts with BEZ235, a dual inhibitor of PI3K/mTOR, resulted in significantly greater suppression of tumor growth compared with either rapamycin or vehicle. 27 This suppression of tumor growth was correlated with reduced markers of proliferation (Ki-67 staining) and modest induction of markers of apoptosis (cleaved caspase 3 staining). In support of the hypothesis that a dual inhibitor of PI3K/mTOR may more effectively suppress both the cap-dependent translation of critical mRNA and TORC2 activity, the superior anti-tumor activity of BEZ235 in the RCC xenografts was associated with suppression of cyclin D1 and HIF-2> expression compared with both vehicle and rapamycin. These preclinical data provide the rationale for the clinical assessment of novel agents targeting the PI3K/Akt/mTOR pathway in RCC.
CLINICAL DATA
One of the earliest such agents to be assessed in RCC was perifosine, an orally available alkylphospholipid that prevents Akt activation by blocking its pleckstrin-homology domainY dependent recruitment to the cell membrane. Perifosine was recently assessed in 2 independent phase II trials in patients with advanced RCC who had failed prior targeted therapy. 28 In Perifosine 228, 24 patients with advanced RCC who had progressed after prior therapy with VEGF-targeted agents and/or cytokines were enrolled and treated with perifosine at 100 mg once daily. In Perifosine 231, 50 patients with advanced RCC were enrolled into 2 groups and treated with perifosine at a dose of 100 mg once daily. Group A included patients who failed a VEGF receptor TKI but not on an mTOR inhibitor, whereas group B included patients who failed both targeted agents. In the combined analysis of 74 patients on both trials, 6 patients The lack of robust clinical activity seen with perifosine has not dampened the enthusiasm for PI3K/Akt as a therapeutic target in RCC, however. Perifosine is an indirect inhibitor of Akt. As mentioned earlier, more reliable inhibition of this pathway may be achieved with the catalytic inhibitors of PI3K/ mTOR or with direct inhibitors of Akt (both catalytic and allosteric). Not surprisingly, several clinical trials with novel inhibitors of PI3K/mTOR and Akt are underway as shown in Table 2 . It is hoped that the results from these clinical trials may provide further validation of the PI3K/Akt pathway as a therapeutic target in RCC.
CONCLUSIONS
TORC1 is a validated therapeutic target in patients with advanced RCC. Substantial scientific rationale exists to assess novel inhibitors of PI3K and Akt in patients with RCC, and these agents are now advancing in clinical development. Parallel with these efforts will be those directed at identifying predictive biomarkers of response to agents targeting the PI3K/Akt/mTOR pathway. Exciting progress has been made in this respect with the recent mutational analysis reported by Voss et al 29 suggesting that the tumor specimens from a subset of robust responders to rapalogues may frequently possess mutations resulting in constitutive activation of mTOR. This, together with data emerging from the Cancer Genome Atlas Project regarding the frequency of mutations in the PI3K/Akt/mTOR pathway in RCC, enhances the expectation that genetic predictors of response to agents targeting this pathway may soon be identified. It is hoped that the combination of improved patients selection strategies and potentially more effective agents will lead in improvements in the therapeutic index of agents directed against this critical pathway. 
